Artiva (ARTV) President Diego Miralles Receives RSU Award

What Happened

• Diego Miralles, President & Head of R&D at Artiva Biotherapeutics (ARTV), received awards totaling 180,000 shares on September 9, 2026. The Form 4 shows two grant entries: 45,000 shares and 135,000 derivative shares, each acquired at $0.00 (no cash paid). Total reported acquisition value: $0. These are equity awards (restricted stock units/derivative awards), not market purchases or sales.

Key Details

• Transaction date: 2026-09-09; Filing date: 2026-09-11 (filed within the normal Form 4 reporting window).
• Grants: 45,000 shares (direct award) + 135,000 derivative shares = 180,000 RSUs; price reported $0.00.
• Footnote F1: Awards represent restricted stock unit grants under the Issuer’s 2024 Equity Incentive Plan.
• Footnote F2: Vesting begins September 8, 2026 — 1/48th of the shares vest monthly over four years (standard multi-year vesting).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.

Context

• These entries are awards (A) — RSUs/derivative awards — meaning Miralles did not buy shares nor sell them; the awards will convert to actual shares as they vest. Such grants are common compensation for executives and do not, by themselves, indicate immediate bullish or bearish trading intent.